HOXA‑AS3 induces tumor progression through the epithelial‑mesenchymal transition pathway in epithelial ovarian cancer.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8501
- By:
- Publication type:
- Article
Works matching IS 1021335X AND DT 2023 AND VI 49 AND IP 3
Results: 17
1
2
Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8500
- By:
- Publication type:
- Article
3
CORRIGENDUM.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8499
- By:
- Publication type:
- Article
4
Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8498
- By:
- Publication type:
- Article
5
RETRACTION.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8493
- By:
- Publication type:
- Article
6
LMP1 mediates tumorigenesis through persistent epigenetic modifications and PGC1β upregulation.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8490
- By:
- Publication type:
- Article
7
AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8489
- By:
- Publication type:
- Article
8
LAPTM5 regulated by FOXP3 promotes the malignant phenotypes of breast cancer through activating the Wnt/β‑catenin pathway.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8497
- By:
- Publication type:
- Article
9
RETRACTION.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8488
- By:
- Publication type:
- Article
10
Role of ubiquitin regulatory X domain‑containing protein 3B in the development of hepatocellular carcinoma (Review).
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8494
- By:
- Publication type:
- Article
11
Modulating epigenetic modifications for cancer therapy (Review).
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8496
- By:
- Publication type:
- Article
12
Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8492
- By:
- Publication type:
- Article
13
CORRIGENDUM.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8491
- Publication type:
- Article
14
miR‑151a‑5p promotes the proliferation and metastasis of colorectal carcinoma cells by targeting AGMAT.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8487
- By:
- Publication type:
- Article
15
GBP2 promotes clear cell renal cell carcinoma progression through immune infiltration and regulation of PD‑L1 expression via STAT1 signaling.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8486
- By:
- Publication type:
- Article
16
Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review).
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8485
- By:
- Publication type:
- Article
17
CORRIGENDUM.
- Published in:
- Oncology Reports, 2023, v. 49, n. 3, p. 1, doi. 10.3892/or.2023.8484
- By:
- Publication type:
- Article